These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11235149)

  • 1. [Novel intermittent GnRHa therapy for patients with endometriosis].
    Tanaka T; Umesaki N
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():124-8. PubMed ID: 11235149
    [No Abstract]   [Full Text] [Related]  

  • 2. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
    Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
    Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and therapy of side effects of gonadotropin-releasing hormone agonist in patients with endometriosis].
    Fang F; Huang M
    Zhonghua Fu Chan Ke Za Zhi; 1999 Aug; 34(8):506-8. PubMed ID: 11360603
    [No Abstract]   [Full Text] [Related]  

  • 4. Leuprolide acetate for the treatment of endometriosis.
    Miller JD
    Prog Clin Biol Res; 1990; 323():337-41. PubMed ID: 2106145
    [No Abstract]   [Full Text] [Related]  

  • 5. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.
    Miller BS; Shukla AR
    Clin Ther; 2010 Sep; 32(10):1749-51. PubMed ID: 21194598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
    Okada H; Heya T; Ogawa Y; Shimamoto T
    J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose effects of progesterone in add-back therapy during GnRHa treatment.
    Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
    J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete remission of OC-resistant catamenial shoulder joint pain and inguinal pain associated with extraperitoneal endometriosis following personalized GnRH agonist therapy.
    Tanaka T; Umesaki N
    Clin Exp Obstet Gynecol; 2009; 36(1):46-8. PubMed ID: 19400418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endometriosis: clinical, histological and morphometric findings before and after Gn-RH agonist therapy].
    Ruwe M; Donhuijsen K; Regidor PA; Leder LD; Schindler AE
    Zentralbl Gynakol; 1998; 120(8):391-8. PubMed ID: 9757546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial.
    Miller JD
    Am J Obstet Gynecol; 2000 Jun; 182(6):1483-8. PubMed ID: 10871469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylactic reaction to different gonadotropin-releasing hormone agonists for the treatment of endometriosis.
    Lüchinger AB; Mijatovic V; Rustemeyer T; Hompes PG
    Am J Med Sci; 2011 Mar; 341(3):240-2. PubMed ID: 21233692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
    Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
    Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis.
    Kang JL; Wang XX; Nie ML; Huang XH
    Gynecol Obstet Invest; 2010; 69(2):73-7. PubMed ID: 19923847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary.
    Maitoko K; Sasaki H
    Fertil Steril; 2004 Aug; 82(2):322-6. PubMed ID: 15302278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Add back therapy for patients with endometriosis].
    Aisaka K
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():129-32. PubMed ID: 11235150
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
    Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
    Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term personalized GnRH agonist therapy without estrogen supplementation for recurrent endometriotic catamenial pneumothorax--case report.
    Tanaka T
    Clin Exp Obstet Gynecol; 2007; 34(3):179-81. PubMed ID: 17937096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.